grant
HCC Ovarian Cancer SPORE
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AddressAdvocateAmericanArchivesBET bromodomain inhibitorBET inhibitorBETiBRCA1BRCA1 Gene ProductBRCA1 ProteinBRCA1 geneBioinformatics coreBioinformatics research coreBioinformatics resource coreBiostatistics CoreBreast Cancer 1 GeneBreast Cancer 1 Gene ProductBreast Cancer Type 1 Susceptibility GeneBreast Cancer Type 1 Susceptibility ProteinBreast-Ovarian Cancer ProteinBromodomain and Extra-Terminal motif inhibitorBromodomains and extra-terminal domain inhibitorCBDCACancer CauseCancer CenterCancer EtiologyCancer PatientCancersCarboplatinCarboplatinoCell BodyCell Communication and SignalingCell Cycle CheckpointCell Cycle Checkpoint GenesCell SignalingCellsCessation of lifeCheckpoint inhibitorChemoresistanceClinicalClinical DataClinical TrialsCollaborationsCost SharingDNA Damage RepairDNA RepairDeathDevelopmentDiagnosisDiseaseDisease ProgressionDisease ResistanceDisorderDoctor of PhilosophyDoseENX-1EZH1EZH2EZH2 geneEarly Onset Gene Breast Cancer 1Early Onset Protein Breast Cancer 1Enhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEnsureEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessErinaceidaeExclusionExperimental ModelsFundingFutureGenerationsGoalsHedgehog (Hh) signal transduction pathwayHedgehogsHereditary Breast Cancer 1HumanHypothetical Protein KIAA0259 GeneImmuneImmune checkpoint inhibitorImmune mediated therapyImmunesImmunologically Directed TherapyImmunotherapyIn VitroIncidenceIndividualInstitutionIntracellular Communication and SignalingInvestigatorsInvestmentsKIAA0259 GeneKMT6KMT6AMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMediatingMesenchymal Progenitor CellMesenchymal Stem CellsMesenchymal progenitorMesenchymal stromal/stem cellsMitoticModelingModern ManMolecularMyeloid-derived suppressor cellsNew AgentsNewly DiagnosedOperative ProceduresOperative Surgical ProceduresOvary CancerP01 MechanismP01 ProgramPARP InhibitorPARP-1 inhibitorPARPiPathologyPatient CarePatient Care DeliveryPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPennsylvaniaPh.D.PhDPhasePhase 1b TrialPhase Ib TrialPlatinumPlatinum BlackPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPositionPositioning AttributePrediction of Response to TherapyPrincipal InvestigatorProgenitor CellsPrognosisProgram Project GrantProgram Research Project GrantsProteinsPt elementRNF53RecurrenceRecurrentRelapseResearchResearch InfrastructureResearch PersonnelResearch Program ProjectsResearchersResistanceResource SharingScienceScientistSignal TransductionSignal Transduction SystemsSignalingSurgicalSurgical InterventionsSurgical ProcedureTOPBP1TOPBP1 GeneTechnologyTestingTimeTopoisomerase (DNA) II Binding Protein GeneTranslational ResearchTranslational ScienceUnscheduled DNA SynthesisWomananti-cancer researchbiological signal transductionbrca 1 genebromodomain extra-terminal inhibitorcancer carecancer microenvironmentcancer researchcare for patientscare of patientscareercareer developmentcaring for patientscell cycle check pointcell cycle check point genecheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemoresistantchemotherapychemotherapy resistancechemotherapy resistantdata resourcedesigndesigningdevelopmentalepigeneticallyexperiencehedgehog signalinghedgehog signaling pathwayhh signaling pathwayhomologous recombinationhomologous recombination deficiencyhomologous recombination repair deficiencyimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive myeloid cellsimprovedimproved outcomein vivoinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinnovateinnovationinnovativemalignancymesenchymal stromal cellmesenchymal stromal progenitor cellsmesenchymal-derived stem cellsmortalitymultidisciplinarymultipotent stromal cellmultipotent stromal progenitormyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm/cancernew diagnosticsnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation diagnosticsnext generation therapeuticsnotchnotch proteinnotch receptorsnovel diagnosticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachovarian cancerpatient oriented outcomespatient responsepatient specific responsepersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentphase 2 trialphase II trialpotential biological markerpotential biomarkerpre-clinicalpreclinicalpredict therapeutic responsepredict therapy responsepreventpreventingprogramsrecruitresistance to diseaseresistance to therapyresistantresistant diseaseresistant to diseaseresistant to therapyresponseresponsive patientsmoothened signaling pathwaystem cellsstromal progenitorstromal stem cellsuccesssuppressive myeloid cellssurgerysynergismtherapeutic agent developmenttherapeutic developmenttherapeutic resistancetherapy predictiontherapy resistanttissue resourcetranslation researchtranslational investigationtreatment predictiontreatment resistancetreatment response predictiontreatment strategytumortumor microenvironment
Description preview
Ovarian cancer (OvCa) has the third highest mortality to incidence ratio and is the fifth leading cause of cancer death in American women. The typical disease course of a patient with OvCa spans four and a half years from the time of diagnosis to death. During the course of patient care, acquired and innate resistance to our most effective and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click